Genelux (GNLX) Q3 2025 earnings summary

Executive summary

• Focused on developing oncolytic viral immunotherapies, with lead candidate Olvi-Vec in late-stage clinical trials for solid tumors and key milestones expected in 2026.

• Enrollment ongoing in Phase 3 ovarian cancer trial; topline data anticipated in H2 2026.

• Interim data from lung cancer programs expected in Q4 2025 and throughout 2026.

• No products approved or revenue from product sales; operations funded by equity offerings and licensing.

• Net loss of $22.9 million for the nine months ended September 30, 2025, with an accumulated deficit of $274.3 million.

Financial highlights

• Cash, cash equivalents, restricted cash, and investments totaled $21.0 million as of September 30, 2025.

• Net loss was $8.0 million for Q3 2025, or $0.21 per share, compared to $6.5 million or $0.19 per share in Q3 2024.

• Research and development expenses increased to $14.2 million for the nine months ended September 30, 2025, mainly due to higher clinical trial and manufacturing costs.

• General and administrative expenses were $9.6 million for the nine months, up year-over-year, driven by higher employee compensation.

• Cash runway expected to extend into Q3 2026.

Outlook and guidance

• Existing cash and investments expected to fund operations into Q3 2026, but substantial additional funding will be needed to complete development and commercialization.

• Topline data from the OnPrime Phase 3 ovarian cancer trial expected in H2 2026.

• Additional interim data from lung cancer trials to be shared in Q4 2025 and through 2026.

• Company expects continued significant operating losses and increased expenses as clinical programs advance.